The therapeutic utility of Strepsils Max Plus is centered on providing targeted, acute, and supportive symptomatic relief for heightened discomfort in the mouth and throat. The product is used within therapeutic areas where supportive symptom management is appropriate, primarily addressing symptoms that interfere with daily functioning.

The lozenge is commonly used across conditions presenting with acute episodes, including the pain associated with severe sore throat, pharyngitis, tonsillitis, and localized irritations such as mouth ulcers. It is applied across domains where additional symptomatic support is needed, helps to address symptom clusters that may become intense or disruptive. The product may assist with supportive, temporary relief for pronounced localized pain and contributes to easing the difficulty of swallowing during acute symptomatic phases. This support helps ease the overall symptom burden and is relevant for managing conditions linked to minor, localized microbial entities.

---

Quick Fact: Relief for Severe Sore Throat

Therapeutic Focus	Primary Benefit	Conditions of Use
Acute Pain	Focused relief for acute pain	Pharyngitis, Tonsillitis
Functional Strain	Assists with pain provoked by swallowing	Severe sore throat, Dysphagia
Localized Irritation	Supports comfort during irritative states	Mouth ulcers, Stomatitis

Regulatory References

1. Irish Health Products Regulatory Authority (HPRA) product information

The official regulatory profile for Strepsils Max Plus establishes clear population constraints based on age, allergy status, and specific physiological states. The medicine is formally allowed for adults and adolescents over 12 years of age.

Use is contraindicated (absolutely prohibited) for individuals with known hypersensitivity to any of the active ingredients or excipients, including persons with a history of allergy to amide-type local anaesthetics. Contraindications also extend to patients with specific rare hereditary sugar intolerances (such as fructose intolerance) and those with a history of, or suspected, methaemoglobinaemia.

The product is not recommended for children under 12 years of age. For pregnant and breastfeeding women, use is similarly not recommended unless it is administered under specific medical supervision. Regulatory documentation also notes that no data is available to establish the safety profile for patients with pre-existing hepatic (liver) or renal (kidney) impairment, and special caution is advised for patients with asthma or bronchospasm.

The regulatory profile for Strepsils Max Plus, which contains Lidocaine Hydrochloride, is primarily defined by the product's topical delivery route. Official regulatory documents note that while a number of drug interactions are theoretically possible with systemic Lidocaine, these are unlikely to be clinically relevant to the patient's safety due to the very low systemic absorption from the oromucosal lozenge.

Pharmacokinetic and Pharmacodynamic Interactions

Pharmacokinetic Interactions: The systemic clearance of Lidocaine is known to involve the hepatic enzymes CYP3A4 and CYP1A2. As documented in the regulatory classification for systemic Lidocaine, medicines that inhibit these enzymes—including substances like Cimetidine, Itraconazole, Erythromycin, or Fluvoxamine—could theoretically reduce Lidocaine's clearance and result in increased plasma concentration if systemic exposure were significant.

Pharmacodynamic Interactions: Theoretical interaction patterns also include the risk of additive cardiac depressant effects when combined with other antiarrhythmic drugs (such as Mexiletine) or beta-adrenoceptor blocking agents.

Interaction-Related Restrictions

Based on the official product information, no substance is explicitly designated as a formal contraindication for co-administration with this lozenge. The official labeling also does not include any mandatory timing separation requirements or documented interactions with food, alcohol, or herbal products.

Interrupting Peripheral Nociceptive Signaling

The primary mechanism involves Lidocaine's ability to block Voltage-Gated Sodium Channels (VGSCs) in sensory nerve endings on the throat lining. By physically obstructing these ion channels, the active ingredient prevents the influx of sodium ions necessary for generating and conducting an electrical impulse, functionally leading to the suppression of afferent nociceptive signaling within the peripheral sensory nerve fibers.

Localized Microbial Membrane Disruption

The combination mechanism includes the antiseptics, Amylmetacresol and Dichlorobenzyl Alcohol, which act via a non-specific mechanism. They target local pathogens by damaging essential microbial proteins and lipid membranes, leading to the loss of cellular integrity. This results in the reduction of localized microbial load, thereby reducing the biological stimuli involved in localized tissue inflammation.

Complementary Dual-Action Synergy

The formulation achieves synergy by combining neural blockade with local chemical disruption. Amylmetacresol further reinforces the anaesthetic action by also blocking VGSCs, resulting in a reinforced sensory interruption mechanism. This pairing results in the concurrent modulation of the neural signaling cascade and the local microbial load.

Administration Scope

The usage of Strepsils Max Plus lozenges is governed by a defined set of parameters establishing a standardized method, frequency, and time limit for administration.

Category	Instruction Summary
Route of administration	Oromucosal. The lozenge is strictly intended for local action on the lining of the mouth and throat.
Dosing schedule	One lozenge per dose for adults and children 12 years and over.
Frequency and limits	Doses may be repeated every 2 hours, as required. The maximum daily dose is 8 lozenges in a 24-hour period.
Timing constraints	Care is advised when eating or drinking immediately after use due to the anaesthetic component.

---

Instruction Classifications (High-Level)

Classification	Description
Administration method type	Topical/Oromucosal.
Frequency pattern	As-needed (pro re nata), governed by a minimum 2-hour interval.
Use-context constraints	Short-term use only, not to exceed a maximum duration of 3 days.

---

Official Use Protocol

The administration of the lozenge requires specific procedural adherence.

Requirements for use include:

• Take one lozenge for administration.
• Allow the lozenge to be sucked slowly in the mouth until fully dissolved.
• Wait a minimum of 2 hours before the next single-lozenge dose, if required.
• Do not exceed the daily limit of 8 lozenges in 24 hours.
• Discontinue use if the maximum course duration of 3 days is reached.

Age-Group Administration Rules

The product is approved for adults and children aged 12 years and over. The lozenge is not recommended for children under 12 years of age, and labeling specifies no requirement for dosage reduction in the elderly population.

Connection to the Overall Use Protocol

The instructions define a rigorous, time-bound protocol for the localized application of this medicine, specifying a singular oromucosal administration route and fixing the dosage at one lozenge per use. This protocol is governed by the 2-hour minimum interval and the 8-lozenge daily maximum, ensuring the defined administration pattern remains within the constraints set for short-term use only.

Evidence for Symptomatic Relief in Acute Sore Throat

Research exploring the lozenge combination was studied for acute throat discomfort, primarily relying on randomized, placebo-controlled trials (RCTs). These short-term studies were designed to explore the relationship between lozenge use and symptomatic patterns in adults. Investigators measured patient-reported outcomes describing discomfort, including the severity of throat soreness and difficulty swallowing (dysphagia). Findings described patterns observed in these measurements, particularly regarding the time until patient-reported sensation changes. However, follow-up durations were limited, meaning research is confined to episodic or acute changes and does not fully characterize long-term outcomes.

---

Evidence for Postoperative Sore Throat (POST) Management

The lozenge combination was also evaluated in research contexts involving a more specific population: adults undergoing surgery with general anaesthesia using Supraglottic Airway Devices (SAD). Controlled clinical trials examined outcomes related to the incidence and intensity of postoperative sore throat. Researchers explored whether administration of the lozenge before surgery was associated with the subsequent incidence and severity of POST. A key limitation is that these results apply only to the studied population, and evidence related to other types of airway management is limited.

---

Key Limitations and Research Uncertainty

Overall, the evidence quality varies, and findings were mixed for the primary endpoint across all reported trials. Data for certain groups remain insufficient; specifically, evidence for the lozenge in children is limited, and there is a lack of published information detailing patterns observed in older adults. Follow-up durations were restricted, providing limited data on prolonged symptomatic support. The research highlights what is known and what is still uncertain, as findings describe group patterns observed under specific study conditions.

Key Studies & References

1. Preoperative amylmetacresol and dichlorobenzyl alcohol with lignocaine lozenge reduces postoperative sore throat following general anaesthesia using supraglottic airway devices: A double-blinded, randomised, placebo-controlled trial
2. Package leaflet: Information for the user Strepsils +Plus Anaesthetic Lozenges (HPRA Regulatory Document)

Common questions about Strepsils Max Plus (FAQ)

Q: What is Strepsils Max Plus used for?

A: Strepsils Max Plus is indicated for the temporary relief of sore throat pain in adults and adolescents aged 12 years and over. It contains an ingredient that acts as a local anesthetic.

---

Q: How does the ingredient in Strepsils Max Plus work?

A: The active ingredient, a local anesthetic, works by temporarily numbing the painful area in the throat. This provides temporary, symptomatic relief.

---

Q: Is Strepsils Max Plus suitable for children?

A: This product is typically approved for use in adults and adolescents aged 12 years and over. Consult the product information or a healthcare professional regarding use in children under 12.

Strepsils Max Plus Lozenges must be stored under specific environmental and security conditions to maintain the product's integrity and quality.

Storage and Shelf-Life Requirements

Requirement	Official Stipulation
Maximum Temperature	Do not store above 25 C
Product Integrity	Do not use the lozenges after the expiry date stated on the carton and blister foil.
Child Safety	Keep out of the sight and reach of children.

The official storage constraint of not storing above 25 C directly ensures the stability of the active ingredients up to the expiry date. The mandatory child safety rule prevents accidental ingestion.

Disposal Instructions

Official disposal guidance prohibits discarding the medicine via wastewater or regular household waste to protect the environment. Patients are instructed to ask a pharmacist how to properly dispose of any Strepsils Max Plus lozenges that are no longer needed or have expired.